Literature DB >> 2527088

Transgenic HLA-DR alpha faithfully reconstitutes IE-controlled immune functions and induces cross-tolerance to E alpha in E alpha 0 mutant mice.

S K Lawrance1, L Karlsson, J Price, V Quaranta, Y Ron, J Sprent, P A Peterson.   

Abstract

We have constructed transgenic mice that express the human class II MHC molecule HLA-DR alpha on a genetic background in which the equivalent endogenous gene, H-2 IE alpha, is not expressed. In these mice, DR alpha complemented the E beta chain such that tissue-specific expression of an interspecies hybrid DR alpha-E beta heterodimer was obtained. Despite 25% amino acid differences between DR alpha and E alpha, immune responsiveness to IE-controlled antigens, clonal deletion of IE-reactive T cells, and alloantigenicity were quantitatively and qualitatively indistinguishable in IE-positive mice and in mice that had integrated at least four copies of the transgene. These results demonstrate a remarkable degree of structural, regulatory, and functional conservation. They also suggest that tolerance induction involves only discrete portions of MHC molecules.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527088     DOI: 10.1016/0092-8674(89)90439-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  26 in total

1.  Tissue-specific expression of the HLA-DRA gene in transgenic mice.

Authors:  P Giacomini; A Ciucci; M R Nicotra; C Nastruzzi; G Feriotto; E Appella; R Gambari; L Pozzi; P G Natali
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

2.  Efficacy of HLA-DRB1∗03:01 and H2E transgenic mouse strains to correlate pathogenic thyroglobulin epitopes for autoimmune thyroiditis.

Authors:  Yi-chi M Kong; Nicholas K Brown; Jeffrey C Flynn; Daniel J McCormick; Vladimir Brusic; Gerald P Morris; Chella S David
Journal:  J Autoimmun       Date:  2011-06-17       Impact factor: 7.094

Review 3.  HLA transgenic mice as humanized mouse models of disease and immunity.

Authors:  V Taneja; C S David
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes.

Authors:  G Feriotto; C Mischiati; N Bianchi; C Rutigliano; P Giacomini; R Gambari
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

5.  The minimal polymorphism of class II E alpha chains is not due to the functional neutrality of mutations.

Authors:  Z T Chu; C Carswell-Crumpton; B C Cole; P P Jones
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  A Newly Recognized Pairing Mechanism of the α- and β-Chains of the Chicken Peptide-MHC Class II Complex.

Authors:  Lijie Zhang; Xiaoying Li; Lizhen Ma; Bing Zhang; Geng Meng; Chun Xia
Journal:  J Immunol       Date:  2020-02-07       Impact factor: 5.422

7.  Replacement of the DR alpha chain with the E alpha chain enhances presentation of Mycoplasma arthritidis superantigen by the human class II DR molecule.

Authors:  T Sawada; R Pergolizzi; K Ito; J Silver; C Atkin; B C Cole; M D Chang
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease.

Authors:  M A Duchosal; S A Eming; P J McConahey; F J Dixon
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

9.  The structure of HLA-DR52c: comparison to other HLA-DRB3 alleles.

Authors:  Shaodong Dai; Frances Crawford; Philippa Marrack; John W Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

10.  A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice.

Authors:  Giuseppina Pennesi; Mary J Mattapallil; Shu-Hui Sun; Dody Avichezer; Phyllis B Silver; Zaruhi Karabekian; Chella S David; Paul A Hargrave; J Hugh McDowell; W Clay Smith; Barbara Wiggert; Larry A Donoso; Chi-Chao Chan; Rachel R Caspi
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.